Soluble Interleukin 2 Receptor IDs Sarcoidosis in UveitisLast Updated: November 13, 2017. Soluble interleukin 2 receptor has slightly better diagnostic value than angiotensin-converting enzyme for sarcoidosis in patients with uveitis, according to a study published online Nov. 9 in JAMA Ophthalmology.
MONDAY, Nov. 13, 2017 (HealthDay News) -- Soluble interleukin 2 receptor (sIL-2R) has slightly better diagnostic value than angiotensin-converting enzyme (ACE) for sarcoidosis in patients with uveitis, according to a study published online Nov. 9 in JAMA Ophthalmology.
Fahriye Groen-Hakan, M.D., from Erasmus University in the Netherlands, and colleagues conducted a cross-sectional retrospective study using data from 249 patients with uveitis. Measurements of sIL-2R and ACE from serum samples were determined and compared as diagnostic biomarkers of sarcoidosis.
The researchers found that patients with sarcoidosis-associated uveitis had the highest mean serum sIL-2R and ACE levels and that patients with HLA-B27-associated and varicella-zoster-virus-associated uveitis also had elevated serum sIL-2R levels. There was a significant correlation for serum sIL-2R and ACE levels but no correlation between uveitis activity and either sIL-2R or ACE. The highest Youden index was 0.45 for sIL-2R alone, corresponding to an optimal cutoff of 4,000 pg/mL and providing sensitivity and specificity of 81 and 64 percent, respectively, alone, and 92 and 58 percent, respectively, when combined with chest radiography. At a cutoff of 6,000 pg/mL, chest radiography combined with sIL-2R yielded 77 and 73 percent sensitivity and specificity. At the standard cutoff of 68U/L, combined chest radiography and serum ACE levels resulted in 70 and 79 percent sensitivity and specificity, respectively.
"This cross-sectional study demonstrates that sIL-2R is a useful marker for diagnosing sarcoidosis in patients with uveitis and has slightly better diagnostic value than ACE," the authors write.
One author disclosed ties to the pharmaceutical industry; the study was partially funded by AbbVie.
|Previous: Prenatal Exposure to ADHD Meds Tied to Neonatal Morbidity||Next: Use of MMR Deficiency Testing in Younger CRC Patients Is Low|
Reader comments on this article are listed below. Review our comments policy.